An open-label, randomized, phase 3 study of inotuzumab ozogamicin administered in combination with rituximab compared to defined investigator�s choice therapy in subjects with relapsed or refractory CD22-positive aggressive non-hodgkin lymphoma who are no
Read time: 1 mins
Last updated:4th Feb 2011
To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an active comparator arm.
|Study start date||2011-02-04|